journal article·2019-12-04Open access

Nanoparticle-based drug delivery in the inner ear: current challenges, limitations and opportunities

Rahul Mittal, Stefanie A. Pena, Angela Zhu, Nicolas Eshraghi, Arian Fesharaki, Elijah J. Horesh, Jeenu Mittal, Adrien A. Eshraghi

Abstract

Hearing loss is the most common neurosensory impairment worldwide. While conductive hearing loss can be managed by surgery, the management of sensorineural hearing loss (SNHL), related to the damage of sensory cells of the inner ear is more challenging to manage medically. Many causes of SNHL such as sudden idiopathic SNHL, Meniere's disease, noise-induced hearing loss, autoimmune hearing loss or hearing loss from exposure to ototoxic substances can benefit from delivery of otoprotective drugs to the inner ear. However, systemic drug delivery through oral, intravenous and intramuscular methods leads to undesirable side effects due to the inner ear's limited blood supply and the relatively poor penetration of the blood-inner ear barrier (BLB). Therefore, there has been an increased interest for the targeted drug delivery to the inner ear using nanoparticles. Drug delivery through nanoparticles offers several advantages including drug stabilization for controlled release and surface modification for specific targeting. Understanding the biocompatibility of nanoparticles with cochlea and developing novel non-invasive delivery methods will promote the translation of nanoparticle-mediated drug delivery for auditory disorders from bench to bedside.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Lipid Membrane Structure and Behavior · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Otolaryngology, Hearing Research Laboratory, University of Miami Miller School of Medicine

Department of Neurological Surgery, University of Miami Miller School of Medicine

References (77)

Show source-provided references
1. 10.1080/14992027.2017.129126410.1080/14992027.2017.1291264 ↗
2. 10.1155/2017/309823010.1155/2017/3098230 ↗
3. 10.1016/j.gene.2018.01.02710.1016/j.gene.2018.01.027 ↗
4. 10.1056/NEJMra161660110.1056/NEJMra1616601 ↗
5. 10.1016/j.mcna.2018.06.01310.1016/j.mcna.2018.06.013 ↗
6. Eshraghi AA, Jung HD, Mittal R. Recent advancements in gene and stem cell based treatment modalities: Potential implications in noise induced hearing loss. Anatomical Record 2018. In press.
7. 10.1002/ar.2258010.1002/ar.22580 ↗
8. 10.1016/j.otc.2015.07.00910.1016/j.otc.2015.07.009 ↗
9. 10.1016/S0140-6736(17)31791-910.1016/S0140-6736(17)31791-9 ↗
10. 10.15537/smj.2015.3.994010.15537/smj.2015.3.9940 ↗
11. 10.1186/1745-6215-15-11010.1186/1745-6215-15-110 ↗
12. 10.1097/MLG.0b013e31816927f010.1097/MLG.0b013e31816927f0 ↗
13. 10.1016/S0194-59980300004-410.1016/S0194-59980300004-4 ↗
14. 10.1097/00129492-200205000-0001210.1097/00129492-200205000-00012 ↗
15. 10.1097/MOO.0b013e32833d30f010.1097/MOO.0b013e32833d30f0 ↗
16. 10.1288/00005537-195607000-0000510.1288/00005537-195607000-00005 ↗
17. 10.1016/j.addr.2016.01.00410.1016/j.addr.2016.01.004 ↗
18. 10.1177/00034894121210031110.1177/000348941212100311 ↗
19. 10.1007/978-1-4939-3615-1_2110.1007/978-1-4939-3615-1_21 ↗
20. 10.1080/17425247.2018.142005510.1080/17425247.2018.1420055 ↗
21. Mittal R, Jhaveri VM, McMurry HS, et al. Recent treatment modalities for cardiovascular diseases with a focus on stem cells, aptamers, exosomes and nanomedicine. Artif Cells Nanomed Biotechnol. 2018;15:1–10.
22. 10.1080/0001648060089510210.1080/00016480600895102 ↗
23. 10.1097/01.mlg.0000180174.81036.5a10.1097/01.mlg.0000180174.81036.5a ↗
24. 10.1002/jbm.b.3105810.1002/jbm.b.31058 ↗
25. 10.1016/j.otohns.2007.04.01310.1016/j.otohns.2007.04.013 ↗
26. 10.1536/ihj.17-55510.1536/ihj.17-555 ↗
27. 10.2147/IJN.S14032510.2147/IJN.S140325 ↗
28. 10.3390/ijms1907197910.3390/ijms19071979 ↗
29. 10.1177/204173141880845510.1177/2041731418808455 ↗
30. 10.1016/j.ijpharm.2010.02.00310.1016/j.ijpharm.2010.02.003 ↗
31. 10.1016/j.heares.2018.03.00210.1016/j.heares.2018.03.002 ↗
32. 10.1016/j.heares.2017.12.01010.1016/j.heares.2017.12.010 ↗
33. 10.3109/1061186X.2013.82907510.3109/1061186X.2013.829075 ↗
34. 10.2147/IJN.S11686710.2147/IJN.S116867 ↗
35. 10.1016/j.ijpharm.2017.08.08410.1016/j.ijpharm.2017.08.084 ↗
36. 10.1021/acs.bioconjchem.8b0063010.1021/acs.bioconjchem.8b00630 ↗
37. 10.1021/acs.bioconjchem.8b0048110.1021/acs.bioconjchem.8b00481 ↗
38. 10.1186/s40824-018-0123-010.1186/s40824-018-0123-0 ↗
39. 10.1097/MLG.0b013e31815f8e4110.1097/MLG.0b013e31815f8e41 ↗
40. 10.1097/MAO.0b013e3181eb32d110.1097/MAO.0b013e3181eb32d1 ↗
41. 10.2147/IJN.S1697310.2147/IJN.S16973 ↗
42. 10.3109/00016489.2015.101227610.3109/00016489.2015.1012276 ↗
43. 10.1080/00016489.2016.125649910.1080/00016489.2016.1256499 ↗
44. 10.1016/j.joto.2015.11.00310.1016/j.joto.2015.11.003 ↗
45. 10.3109/0001648880912510710.3109/00016488809125107 ↗
46. 10.1007/s00424-013-1421-y10.1007/s00424-013-1421-y ↗
47. 10.1007/s00424-015-1720-610.1007/s00424-015-1720-6 ↗
48. 10.1097/MAO.0b013e31818658ea10.1097/MAO.0b013e31818658ea ↗
49. 10.1080/00016480130036655210.1080/000164801300366552 ↗
50. 10.1128/iai.63.4.1305-1310.199510.1128/iai.63.4.1305-1310.1995 ↗
51. 10.1016/S0378-5955(01)00223-410.1016/S0378-5955(01)00223-4 ↗
52. 10.1016/j.actbio.2017.02.01910.1016/j.actbio.2017.02.019 ↗
53. 10.1038/nbt.333010.1038/nbt.3330 ↗
54. 10.2147/IJN.S8176210.2147/IJN.S81762 ↗
55. 10.4103/0366-6999.14920210.4103/0366-6999.149202 ↗
56. 10.2147/IJN.S2971210.2147/IJN.S29712 ↗
57. 10.1016/j.jconrel.2018.04.02810.1016/j.jconrel.2018.04.028 ↗
58. 10.1097/MAO.000000000000044510.1097/MAO.0000000000000445 ↗
59. 10.1186/s40035-015-0041-110.1186/s40035-015-0041-1 ↗
60. 10.1016/j.canlet.2017.09.04310.1016/j.canlet.2017.09.043 ↗
61. 10.1002/wnan.145210.1002/wnan.1452 ↗
62. 10.1021/acs.chemrev.5b0058910.1021/acs.chemrev.5b00589 ↗
63. 10.1016/B978-0-12-416020-0.00007-310.1016/B978-0-12-416020-0.00007-3 ↗
64. 10.2165/00063030-200822050-0000410.2165/00063030-200822050-00004 ↗
65. 10.1038/gt.2017.4110.1038/gt.2017.41 ↗
66. 10.1080/21691401.2017.128249610.1080/21691401.2017.1282496 ↗
67. 10.1007/s10439-016-1583-910.1007/s10439-016-1583-9 ↗
68. 10.1016/j.actbio.2013.12.06110.1016/j.actbio.2013.12.061 ↗
69. 10.3390/polym303137710.3390/polym3031377 ↗
70. 10.1155/2014/18054910.1155/2014/180549 ↗
71. 10.4155/tde.15.2810.4155/tde.15.28 ↗
72. 10.1166/jbn.2016.212210.1166/jbn.2016.2122 ↗
73. 10.1016/j.colsurfb.2017.06.01510.1016/j.colsurfb.2017.06.015 ↗
74. 10.1088/1361-648X/aa60f310.1088/1361-648X/aa60f3 ↗
75. Kayyali MN, Brake L, Ramsey AJ, et al. A novel nano-approach for targeted inner ear imaging. J Nanomed Nanotechnol. 2017;8:456.
76. Zakeri-Milani P, Mussa Farkhani S, Shirani A, et al. Cellular uptake and anti-tumor activity of gemcitabine conjugated with new amphiphilic cell penetrating peptides. Excli J. 2017;16:650–662.
77. 10.1080/21691401.2017.137901610.1080/21691401.2017.1379016 ↗